Lieberman on Psychiatry

• Explaining the Renewed Interest in Tardive Dyskinesia   According to Dr Jeffrey Lieberman, it's not science but marketing that's driving the rise in TD coverage.
  Medscape Psychiatry, February 2019
• Addressing Military Mental Health: A Proposed Solution   Dr Jeffrey Lieberman discusses the current stigma around military mental health and proposes a solution to deliver improved care to our veteran population and their families.
  Medscape Psychiatry, December 2018
• Death Is Not an Acceptable Outcome for Mental Illness   Suicide and mental illness: Dr Jeffrey Lieberman discusses recent events and the need for improved access to treatment.
  Medscape Psychiatry, December 2018
• Kanye West, Elon Musk, and the Complexities of Armchair Psychiatry   Commenting on the actions of public figures: Dr Jeffrey Lieberman discusses the 25th Amendment and the Goldwater Rule.
  Medscape Psychiatry, November 2018
• Why Do We Continue to Doubt Antidepressants' Efficacy? Dr Jeffrey Lieberman on why 'lies, damned lies, and statistics' may account for the backlash against antidepressants.
  Medscape Psychiatry, June 2018
• Breaking the Cycle of Violence in Patients With Mental Illness   Prompted by the recent shooting in Parkland, Florida, Dr Jeffrey Lieberman discusses what he considers the root cause of such senseless and violent acts: how America views and treats mental illness.
  Medscape Psychiatry, March 2018
• Would President Trump Pass the Air Force's Nuclear Evaluation?   Dr Lieberman suggests that candidates for President should pass a psychological evaluation similar to the Air Force's PRP to determine their mental health.
  Medscape Psychiatry, January 2018
• The Dangers of Speculating About Trump's Mental Health   A book offering clinical assessments of President Trump's mental health has become a best seller. It's also a threat to psychiatry's reputation, says Dr Jeffrey Lieberman.
  Medscape Psychiatry, December 2017
• Misplaced Ecstasy? Questioning the Role of Psychedelics as Therapy   Dr Jeffrey Lieberman scrutinizes the current trend of repurposing 'feel good' drugs for serious mental conditions.
  Medscape Psychiatry, October 2017
• One Doctor's Ketamine Concern   After receiving a solicitation from a ketamine clinic, Dr Jeffrey Lieberman did some digging. What he found troubled him.
  Medscape Psychiatry, October 2017
• Revolutionizing Mental Health Care Through Technology   Dr Lieberman urges the private sector and academia to move ahead with smartphone and mobile device technologies.
  Medscape Psychiatry, August 2017
• One Step Forward, Two Steps Back: The US Healthcare Struggle   US healthcare policy is a Gordian knot, says Dr Lieberman, and current congressional machinations will not solve it.
  Medscape Psychiatry, July 2017
• Politics Are Sick. Time to Call a Doctor?   By infusing government with scientists and clinicians, we might get a healthier democracy, Dr Jeffrey Lieberman argues.
  Medscape Psychiatry, May 2017
• Two Major Developments in Psychiatry   Dr Jeffrey Lieberman discusses the process of updating the DSM on an ongoing basis, along with a rigorous new study on antipsychotic therapies.
  Medscape Psychiatry, May 2017
• What Should the Public Know About a President's Mental Health? Dr Jeffrey Lieberman argues that it's time we devised a system of vetting the physical and mental health of presidential candidates.
  Medscape Psychiatry, May 2017
• 'I'm Mad as Hell!': Healthcare in America Today   Dr Lieberman offers perspective on the healthcare landscape in America, repeal of the Affordable Care Act, and fiscal implications associated with clinical research and NIH funding.
  Medscape Psychiatry, March 2017
• Mental Health Docs Must Resist Armchair Diagnoses of Trump   According to Dr Jeffrey Lieberman, history shows a slippery slope away from ethics when psychiatrists, psychologists, and analysts play politics.
  Medscape Psychiatry, February 2017
• An Extraordinary Legislative Gain for Mental Health Care   The 21st Century Cures Act is broad in scope and potential impact on mental health care and research--and 'a marvelous synergy of good legislation,' declares Dr Lieberman.
  Medscape Psychiatry, December 2016
• Our Short-Sighted Mental Health Policies   Dr Lieberman laments our self-defeating inaction on mental health care and challenges all of us to redouble our efforts and press for change.
  Medscape Psychiatry, November 2016
• It's Morning in America for Mental Health Care   For the first time in recent memory, a presidential candidate has elevated mental health care to the level of a major priority, says Dr Lieberman.
  Medscape Psychiatry, September 2016
• Mental Health and the Presidency Dr Jeffrey Lieberman discusses the personality traits he feels drive people to seek political office.
  Medscape Psychiatry, August 2016
• Historic Day or a Missed Opportunity in Mental Health Care?   HR 2646 could be a mental health care game changer, but only if its many consequential elements are retained by the Senate, says Dr Lieberman.
  Medscape Psychiatry, July 2016
• Improving Drug Trials: Lessons Learned From Aripiprazole   Dr Lieberman discusses the FDA's recent warning about the side effects of aripiprazole, what we can learn from this, and how we can better manage a new drug's uncertain potential in the future.
  Medscape Psychiatry, May 2016
• While Rome Burns: Addressing Rising Suicide Rates   In the wake of rising suicide rates, Dr Lieberman urges us not to follow Nero's lead but to act to change the trajectory of these shocking statistics.
  Medscape Psychiatry, May 2016
• Genetics and Psychiatry: Let's Proceed With Caution   Dr Lieberman discusses three publications that illustrate the increasing role of genomics in psychiatry, cautioning against getting too excited too soon.
  Medscape Psychiatry, April 2016
• Two Bright Lights on the Healthcare Horizon   Dr Lieberman describes new healthcare legislation that can reverse the erosion of healthcare research/development of the past decade and improve your healthcare practice.
  Medscape Psychiatry, August 2015
• Psychedelic Drugs Redux: Don't Leapfrog the Research   Research trials of psychedelic drugs were truncated by the politics of the 1960s. Dr Lieberman explains why we need to begin studying them again, before public opinion gets ahead of what we know.
  Medscape Psychiatry, July 2015
• Should Celebrities Speak Out About Illness?   What is the fallout from celebrities championing causes in health and illness? Dr Jeffrey A. Lieberman discusses negatives and positives.
  Medscape Psychiatry, March 2015
• Second Chance for Mental Health Crisis Act   Congressman Tim Murphy takes another stab at pushing this landmark legislation across the finish line. Dr Lieberman explains how important these long-overdue reforms are for everyone.
  Medscape Psychiatry, February 2015
• What Does the New York Times Have Against Psychiatry?   Dr Jeffrey Lieberman's not-so-pleased reaction to a recent New York Times article on mental illness.
  Medscape Psychiatry, February 2015
• Ketamine in Psychiatry: Take Care   Dr Lieberman discusses the experience with ketamine and its promise for patients with refractory psychiatric conditions but cautions that it be used carefully and in a professional and rigorous way.
  Medscape Psychiatry, February 2015
• Understanding the Brain   Dr Jeffrey Lieberman discusses our ongoing attempt to understand the brain and thereby improve psychiatric care.
  Medscape Psychiatry, September 2014
• Robin Williams' Suicide Had Nothing to Do With Demons   In the wake of actor Robin Williams' tragic suicide, Dr. Jeffrey Lieberman discusses how we can better recognize and treat factors that predispose to suicidality.
  Medscape Psychiatry, September 2014
• A New 'Champion of Mental Health Care'   Welcome new legislation has the potential to further mental health research and improve patient care.
  Medscape Psychiatry, April 2014
• US Biomedical Funding Slows, Asia's Explodes   American Psychiatric Association president Dr. Jeffrey Lieberman discusses 2 new reports reflecting the bleak state of biomedical research funding in the United States.
  Medscape Psychiatry, February 2014
• Explaining the Rise in ADHD   American Psychiatric Association president Dr. Jeffrey Lieberman discusses a recent New York Times article looking at the sky-high rates of ADHD in the United States.
  Medscape Psychiatry, January 2014
• So Near, Yet So Far: Achieving Parity in Mental Health Care APA president Dr. Jeffrey Lieberman on how mental health parity and healthcare reform might affect the field of psychiatry.
  Medscape Psychiatry, December 2013
• An Important Look at Mortality in Mental Illness   Is the increased mortality risk among patients with psychiatric illness worsened by psychopharmacologic agents?
  Medscape Psychiatry, October 2013
• The 'Darkest Year Ever' for the NIH?   American Psychiatric Association President Dr. Jeffrey Lieberman on how government policies are out of sync with our country's medical needs.
  Medscape Psychiatry, October 2013
• How Will Healthcare Reform Affect Psychiatry Coverage?   APA president Dr. Jeffrey Lieberman discusses the need to ensure that mental health parity is incorporated in US healthcare reform.
  Medscape Psychiatry, September 2013
• A Mental Health Commitment in Washington   APA President Dr. Jeffrey Lieberman discusses a recent White House event bringing together clinicians, politicians, and celebrities to discuss how US mental healthcare can be improved.
  Medscape Psychiatry, July 2013
• Psychiatry Gets More Scientific   DSM-5 has been criticized for being unscientific. But a promising study suggests that useful biomarkers might be around the corner.
  Medscape Psychiatry, June 2013
• DSM-5: Setting the Record Straight President-elect of the American Psychiatric Association, Dr. Jeffrey Lieberman, comments on his recent joint statement with the NIMH and the future of psychiatric diagnostics.
  Medscape Psychiatry, May 2013
• A Psychiatrist on Hollywood   In the wake of the Academy Awards, Dr. Jeffrey Lieberman reviews 2 recent movies portraying mental illness.
  Medscape Psychiatry, April 2013
• A Long Way From 'Insanity and Idiocy'   In late 2012, the DSM-5 was approved by the APA. APA President-elect Dr. Jeffrey Lieberman discusses how far psychiatry has come, where it needs to go, and why it's the right time for a DSM revision.
  Medscape Psychiatry, January 2013
• Don't Turn Your Back on Industry, but Keep It Honest   APA President-elect Dr. Jeffrey Lieberman responds to a recent Washington Post article criticizing the pharmaceutical industry's influence on drug research.
  Medscape Psychiatry, December 2012
• Runaway Psychotropic Prescribing   Dr. Jeffrey Lieberman addresses the high rate of psychotropic use in the United States. Is it cause for concern?
  Medscape Psychiatry, November 2012
• Psychiatric Drug Development: Hope Around the Corner?   Three promising psychiatric drug trials were halted recently, reflecting the gloomy state of drug development in psychiatry. But help might be on the way.
  Medscape Psychiatry, September 2012
• When Healthcare Gets a Cold, Psychiatry Gets Pneumonia   Dr. Jeffrey Lieberman discusses the future of psychiatry given that healthcare reform is now a reality.
  Medscape Psychiatry, August 2012
• Grief, the DSM-5, and Avoiding Checklist Psychiatry   APA President-Elect Jeffrey Lieberman discusses the ongoing grief vs depression controversy. Plus, a call to place more emphasis on etiology in psychiatric diagnosis.
  Medscape Psychiatry, June 2012
• A Major Transformation in Psychiatry?   Dr. Jeffrey Lieberman discusses new and investigational laboratory and imaging tests that have the potential to greatly advance psychiatric diagnosis.
  Medscape Psychiatry, May 2012
• Still More Concerns for Psychiatrists?   In the face of continuing mental health care funding cuts, how can psychiatrists call to arms?
  Medscape Psychiatry, April 2012
• Cedars-Sinai Nixing Psychiatric Services -- Now What?   In a cost-containment effort, LA's Cedars-Sinai Medical Center will cut most of its psychiatric services this year. Will healthcare reform help prevent further cutbacks across the United States?
  Medscape Psychiatry, February 2012
• Practicing 'Rational' Polypharmacy in Psychiatry   Dr. Jeffrey Lieberman discusses a promising adjunct for cognitive impairment in schizophrenia, plus other efforts toward more targeted, efficacious polypharmacy in psychiatry.
  Medscape Psychiatry, January 2012
• Mental Health Care: The Times They Are a-Changin'   Medical homes. Accountable care organizations. Dr. Jeffrey Lieberman discusses how psychiatry fits into these and other evolving healthcare models.
  Medscape Psychiatry, December 2011
• Psychiatric Diagnosis in the Lab: How Far Off Are We?   Biomarkers, genetic testing, and imaging modalities have shown promise in psychiatric diagnosis. Dr. Jeffrey Lieberman discusses the current and future roles of these approaches in clinical practice.
  Medscape Psychiatry, September 2011
• Coping With Disaster: The Mental Health Effects of Trauma   It's been 10 years since the devastating events of 9/11. How were clinicians and patients impacted by the tragedy, and what are the mental health consequences of disasters and traumatic events?
  Medscape Psychiatry, September 2011
• Antipsychotics: To Switch or Not to Switch?   Dr. Jeffrey Lieberman discusses the often challenging decision of when and how to switch antipsychotic medications in patients with schizophrenia.
  Medscape Psychiatry, August 2011
• Should Clinician Prescribing Data Be Sold?   Dr. Jeffrey Lieberman discusses the ethics of disclosing or selling clinician prescribing data to private entities such as drug manufacturers.
  Medscape Psychiatry, July 2011
• APA 2011: What Not to Miss   Dr. Jeffrey Lieberman previews APA 2011 presentations on substance abuse, the DSM, and psychiatry's future, among other sessions not to miss at this year's meeting.
  Medscape Psychiatry, May 2011
• Antipsychotics: Injectables vs Orals   How does long-acting injectable risperidone stack up against oral risperidone in terms of safety and efficacy? Dr. Jeffrey Lieberman discusses a recent NEJM article comparing these agents.
  Medscape Psychiatry, April 2011
• Antipsychotics: In Search of the Holy Grail   Dr. Jeffrey Lieberman compares the mechanisms of action of existing antipsychotic drugs and postulates where drug development needs to go.
  Medscape Psychiatry, January 2011
• How Will a Divided Congress Impact Healthcare Reform?   Dr. Jeffrey Lieberman discusses what effects a GOP majority in the House of Representatives could have on healthcare reform.
  Medscape Psychiatry, November 2010
• A Simple Way to Avoid Malpractice Litigation   Dr. Jeffrey Lieberman discusses physician vulnerability to legal accusations and offers a simple means of reducing malpractice risk.
  Medscape Psychiatry, October 2010
• Psychiatric Care Shortage: What the Future Holds   Dr. Jeffrey Lieberman discusses the worsening shortage of psychiatric resources and how our population's future mental health needs can be met.
  Medscape Psychiatry, September 2010
• Malpractice Watch: Keep an Eye Out for Side Effects   Dr. Jeffrey Lieberman discusses the importance of monitoring and means of addressing side effects associated with antipsychotic therapy.
  Medscape Psychiatry, August 2010
• Depression in Pregnancy: It's Not Just the Mothers   Dr. Jeffrey Lieberman discusses the unmet clinical needs and treatment issues associated with peri- and postpartum depression.
  Medscape Psychiatry, July 2010
• Metabolic Abnormalities With Antipsychotics: A Management Update   Dr. Jeffrey Lieberman highlights strategies for managing metabolic disturbances and weight gain associated with atypical antipsychotic therapy.
  Medscape Psychiatry, May 2010
• Psychiatric Drug Development: Why So Slow?   Dr. Jeffrey A. Lieberman discusses the slow nature of psychotropic drug development, the need for novel treatments, and the recession's impact on therapeutic advances in psychiatry.
  Medscape Psychiatry, May 2010
• Antidepressant Efficacy Correlates With Depression Severity   In January, JAMA published a report claiming that certain antidepressants are not effective in mild-to-moderate depression. Should we be surprised? Dr. Jeffrey A. Lieberman discusses the implications of these findings.
  Medscape Psychiatry, March 2010
• Omega-3 Fatty Acids in the Prevention of Psychotic Disorders?   Recognizing and managing prodromal psychosis is hampered by nonspecific diagnostic criteria and lack of appropriate therapies. Dr. Jeffrey Lieberman discusses a new study suggesting that long-chain omega-3 fatty acids may prevent progression to a psychotic disorder.
  Medscape Psychiatry, March 2010
• Morbidity and Mortality in Schizophrenia: The Mystery of Clozapine   In this video blog, Dr. Lieberman comments on a recent study in the Lancet that investigates the long-term contribution of antipsychotic drugs to mortality in patients with schizophrenia.
  Medscape Psychiatry, January 2010
• The Gospel on Antipsychotic Drugs According to CATIE   Dr. Lieberman discusses the efficacy of antipsychotic drugs in patients with schizophrenia in his latest video blog.
  Medscape Psychiatry, October 2009
• Treating Schizophrenia and Related Psychotic Disorders   In the first part of a new video blog series, Dr. Jeffrey Lieberman discusses the treatment of schizophrenia and related psychotic disorders.
  Medscape Psychiatry, September 2009